

NantHealth to Present at the Deutsche Bank 42nd Annual HealthCare Conference on May 4, 2017

May 3, 2017

CULVER CITY, Calif.--(BUSINESS WIRE)-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, announced today that the company will present at the Deutsche Bank 42nd Annual Health Care Conference at 10:40 a.m. ET, on Thursday, May 4, 2017 at the InterContinental Boston Hotel.

The company also said that Robert Watson, who will present on behalf of NantHealth at the Deutsche conference, is transitioning from his role as president and chief growth officer to consultant for the company, in order to relocate to the East Coast for family reasons.

"In his transitional role, Bob will remain an important member of our team through the end of the year," said Patrick Soon-Shiong, M.D., Chief Executive Officer and Chairman of NantHealth. "Bob oversaw the integration of several acquisitions and was instrumental in leading our company's transition from a private to public company."

"I am very grateful for the time I spent at NantHealth and to have launched the initial public offering," said Watson. "I am a firm believer in the immense value GPS cancer will bring to the thousands of cancer patients who will benefit from the information derived from this breakthrough test. I am confident that NantHealth will continue as a leading evidence-based personalized healthcare company in the years ahead."

The company will post to its website the slides presented at the Deutsche Bank 42nd Annual Health Care Conference.

About NantHealth, Inc.

NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth's unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit www.nanthealth.com.



View source version on [businesswire.com](http://www.businesswire.com/news/home/20170503006827/en/): <http://www.businesswire.com/news/home/20170503006827/en/>

for NantHealth, Inc.
Investor Contact:
Robert Jaffe
424.288.4098
rjaffe@rjaffeco.com

Source: NantHealth, Inc.